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Abstract
Hyperlipidemia affects millions of people worldwide and is a major risk factor for cardiovascular
disease. People with hyperlipidemia have elevated levels of serum cholesterol and an increased
risk of thrombosis. Studies have suggested that oxidized lipoproteins, such as oxidized low-
density lipoprotein (oxLDL), contribute to the development of a pro-thrombotic state. In this
review, we discuss our recent studies demonstrating a role for hematopoietic cell-derived tissue
factor (TF) expression in the activation of coagulation and increased thrombosis associated with
hyperlipidemia. In addition, we investigated the effect of simvastatin on TF expression and
coagulation. We found that simvastatin reduced leukocyte TF expression, TF+ microparticles and
coagulation. These results and earlier studies suggest that the anti-coagulant activity of statins is
due, in part, to their ability to reduce monocyte TF expression in patients with cardiovascular
disease.
Introduction
Lipids are transported in blood within lipoprotein particles. Hyperlipidemia describes a
condition in which there are elevated levels of serum lipids. In the United States it is
estimated that ~33.5% of the adult population has elevated serum cholesterol levels (≥240
mg/dL) (Go, Mozaffarian et al. 2013). Hyperlipidemia is a risk factor for the development of
atherosclerosis because the excess lipids in the blood accumulate in the walls of arteries.
Oxidation of low-density lipoprotein (LDL) results in the generation of oxidized (ox)LDL,
which is a heterogeneous mixture of oxidized lipids and proteins (Levitan, Volkov et al.
2010). One bioactive oxidized lipid within oxLDL is oxidized 1-palmitoyl-2-arachidonoyl-
sn-glycero-3-phosphoryl-choline (oxPAPC). OxLDL binds a variety of cellular receptors on
macrophages, monocytes, vascular smooth muscle cells (VSMCs) and endothelial cells
(ECs). These receptors include the scavenger receptors SRAI/II, SRBI/II, CD36 and the
immune receptor toll-like receptor 4 (TLR4) (Boullier, Bird et al. 2001, Kunjathoor,
Febbraio et al. 2002). A recent study found that oxLDL activation of mouse macrophages
and a human monocytic cell line called THP-1 is mediated by a CD36/TLR4/TLR6
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heterotrimeric receptor complex (Stewart, Stuart et al. 2010). OxLDL also increases TLR4
expression in macrophages, and hyperlipidemia is associated with increased TLR4
expression on circulating monocytes (Xu, Shah et al. 2001, Methe, Kim et al. 2005).
TF is a transmembrane receptor that binds factor VII/VIIa and activates the clotting cascade
(Mackman 2009). It plays an essential role in hemostasis since inactivation of the TF gene in
mice is associated with embryonic lethality. Exposure of monocytes to bacterial LPS
induces TF expression (Mackman, Brand et al. 1991). It is thought that TF expression by
monocytes is part of the host response to infection and helps prevent dissemination of the
infection. However, monocyte TF expression can also contribute to thrombosis.
Hyperlipidemia is associated with a pro-thrombotic state (Eitzman, Westrick et al. 2000,
Podrez, Byzova et al. 2007, Diaz, Ballard-Lipka et al. 2012). Recent studies have
demonstrated that hyperlipidemia and oxLDL activates platelets via CD36 (Podrez, Byzova
et al. 2007). Studies have demonstrated that circulating monocytes from hyperlipidemic
individuals have higher levels of tissue factor (TF) compared with healthy controls (Ferro,
Basili et al. 1997, Puccetti, Bruni et al. 2000). In addition, acute coronary syndrome patients
have elevated levels of both circulating monocyte-derived microparticles (MPs) as well as
TF+ MPs (Matsumoto, Nomura et al. 2004, Morel, Pereira et al. 2009, Owens and Mackman
2011). MPs are small membrane vesicles released from activated and apoptotic cells and
elevated levels are observed in the circulation in various pathological conditions (Owens and
Mackman 2011). Finally, injection of oxidized lipids also increased TF expression in blood
cells in mice (Kadl, Huber et al. 2002).
Rupture of atherosclerotic plaques induces the formation of intravascular thrombi that may
occlude blood flow and lead to myocardial infarction and stroke. Atherosclerotic plaques
contain high levels of TF (Wilcox, Smith et al. 1989). In addition, atherosclerotic plaques
contain high levels of monocyte-derived TF+ MPs (Leroyer, Isobe et al. 2007). Platelets are
activated by the exposed collagen whereas the clotting cascade is activated by TF within the
plaque (Owens and Mackman 2012). In vitro studies have shown that oxLDL induces TF
expression in monocyte-derived macrophages, ECs and VSMCs (Drake, Hannani et al.
1991, Cui, Penn et al. 1999, Ross 1999, Levitan, Volkov et al. 2010, Meisel, Xu et al. 2011).
Additionally, oxPAPC induces TF expression in human endothelial cells in a TLR2 and
Egr-1-dependent manner (Bochkov, Mechtcheriakova et al. 2002).
The statin family of drugs is the most widely prescribed medication class in the world.
Statins lower cholesterol levels in hyperlipidemic patients by inhibiting the rate limiting
enzyme in cholesterol synthesis 3-hydroxy-3-methylglutaryl co-enzyme A reductase (HMG-
CoA reductase) that is present in the liver. However, statins also have additional activities
independent of their lipid lowering activity, including anti-oxidant, anti-inflammatory, and
anti-thrombotic activities (Di Garbo, Bono et al. 2000, Albert, Danielson et al. 2001, Liao
and Laufs 2005). Statins also reduce TLR4 expression in human monocytes both in vitro and
in vivo (Methe, Kim et al. 2005). Recent studies have found that statins also decrease
venous thrombosis in a mouse model and in humans (Glynn, Danielson et al. 2009,
Patterson, Zhang et al. 2013).
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Statins have been found to reduce TF expression in atherosclerotic plaques in
hyperlipidemic mice, rabbits, pigs and monkeys without affecting lipid levels (Aikawa,
Rabkin et al. 2001, Sukhova, Williams et al. 2002, Bea, Blessing et al. 2003, Casani,
Sanchez-Gomez et al. 2005, Monetti, Canavesi et al. 2007). Moreover, simvastatin reduced
monocyte TF expression in hypercholesterolemic patients (Ferro, Basili et al. 1997). In the
Jupiter study the authors speculated that the decrease in venous thrombosis may be due to
rosuvastatin inhibition of monocte TF expression. In vitro studies demonstrated that statins
can directly inhibit inducible TF expression in various cells types, including monocytes and
macrophages (Colli, Eligini et al. 1997, Ferro, Basili et al. 1997, Ferro, Basili et al. 2000,
Aikawa, Rabkin et al. 2001).
This review will focus on our recent study examining the role of TF in the activation of
coagulation in animal models of hyperlipidemia and the effect of administration of
simvastatin (Owens, Passam et al. 2012).
OxLDL induces TF expression in monocytic cells and human monocytes in
vitro
We found that oxLDL, but not LDL, increased TF expression in both human THP-1
monocytic cells and human monocytes (Owens, Passam et al. 2012). OxLDL also increased
the number TF+ MPs present in the culture medium. Inhibition of TLR4 reduced oxLDL
induction of monocytic TF expression and TF+ MPs (Owens, Passam et al. 2012). We are
currently investigating the intracellular signaling pathways and transcription factors that
mediate oxLDL induction of TF gene expression in monocytic cells. Next, we examined the
effect of simvastatin on oxLDL induction of TF expression in THP-1 cells and human
monocytes. Pretreatment of THP-1 cells and human monocytes with simvastatin
significantly reduced oxLDL induction of both cellular and MP TF activity (Owens, Passam
et al. 2012) (Figure 1). Previous studies have proposed that statins reduce TF expression by
inhibiting geranylgeranyl pyrophosphate (GGPP)-dependent prenylation of Rho A (Eto,
Kozai et al. 2002, Nagata, Ishibashi et al. 2002). An alternative possibility is that simvastatin
activates the phosphatidylinositol Akt pathway that has been shown to negatively regulate
LPS induction of TF gene expression in monocytic cells (Guha and Mackman 2002). We are
currently investigating the mechanism by which simvastatin reduces oxLDL induction of TF
gene expression in monocytic cells.
Hyperlipidemic induction of leukocyteTF expression produces a
prothrombotic state in animal models
We hypothesized that the pro-thrombotic state associated with hyperlipidemia is due to
oxLDL induction of monocyte TF expression (Owens, Passam et al. 2012). We measured
levels of TF+ MPs as a biomarker of monocyte activation. Consistent with our hypothesis,
we found that patients with familial hyperlipidemia had an elevated level of circulating
oxLDL and this correlated with levels of MP TF activity and activation of coagulation
(Owens, Passam et al. 2012). A high fat diet led to time-dependent increases in plasma
oxLDL, white blood cell TF activity, MP TF activity, and activation of coagulation in
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LDLr−/− mice and monkeys. Importantly, inhibition of TF in hyperlipidemic LDLr−/− mice
reduced the activation of coagulation. Furthermore, hyperlipidemic LDLr−/− mice with a
deficiency of TF in hematopoietic cells had significantly less MP TF activity and the
activation of coagulation. We also found that LDLr−/− mice deficient in either TLR4 or
TLR6 had a significantly reduced level of MP TF activity and activation of coagulation
compared with LDLr−/− mice with wild-type levels of TLR4 and TLR6. Interestingly,
hyperlipidemia also led to increased CD36, TLR4, and TLR6 mRNA expression in
circulating monocytes (Owens, Passam et al. 2012). These results suggest that monocyte TF
drives the activation of coagulation in hyperlipidemic animal models and in humans.
Simvastatin, TF expression and activation of coagulation in hyperlipidemic
animal models
We examined the effect of administration of simvastatin to hyperlipidemic LDLr−/− mice
and monkeys on circulating TF expression and the activation of coagulation (Owens,
Passam et al. 2012). Simvastatin reduced levels of oxLDL, leukocyte TF expression, MP TF
activity, and the activation of coagulation without affecting lipid levels (Figure 1).
Moreover, we also found that simvastatin reduced the inflammatory markers IL-6 and C-
reactive protein in hyperlipidemic LDLr−/− mice and hypercholesterolemic monkeys,
respectively. The observed reduction in oxLDL may be due to the inhibition of oxidative
modification of LDL or enhanced clearance of the oxidized phospholipids (Rosenson 2004,
Tsimikas, Witztum et al. 2004). We also found simvastatin reduced the expression of TLR4,
TLR6, and CD36 mRNA in peripheral monocytes in hypercholesterolemic monkeys
(Owens, Passam et al. 2012).
Conclusions
Hyperlipidemia produces a pro-thrombotic state in animal models by increasing TF
expression on circulating monocytes and via the release of highly pro-coagulant TF+ MPs.
This “circulating TF” may also contribute to the formation of an occlusive thrombus after
plaque rupture. We propose that circulating TF+ MPs may be a useful biomarker to identify
patients that are at high risk for both arterial and venous thrombosis. In addition, they may
be useful in monitoring the effectiveness of various interventional therapies, such as statin
therapy, on reducing monocyte activation. More studies are needed to better understand how
statins reduce the levels of oxLDL, the CD36/TLR4/TLR6 receptor complex and monocyte
TF expression so that a new generation of anti-coagulant drugs can be developed for patients
with hyperlipidemia. Targeting the inducible, pathologic TF expression without affecting the
constitutive, hemostatic TF should be a safer strategy to reduce thrombosis in patients with
cardiovascular disease.
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Proposed sites of simvastatin inhibition of monocytic TF expression. LDL is converted to
oxLDL which binds to a CD36/TLR4/TLR6 heterotrimeric complex on the surface of
circulating monocyte that activates various intracellular signaling pathways and transcription
factors required for TF gene expression. This results in increased TF protein expression on
the surface of the monocyte, increased CD36/TLR4/TLR6 expression, and release of TF+
MPs. Simvastatin reduces the levels of oxLDL, levels of the CD36/TLR4/TLR6 complex
and TF expression.
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